Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 6/20 | 0.33 |
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126930 | 0.78 | TSHR (0.33) | PTGS1KCNH2 | |
| SCHEMBL10311712 | 0.76 | PIK3CD (0.42) | FPR2PIK3CDCNR1CNR2TRPA1 | |
| SCHEMBL4128472 | 0.75 | USP2 (0.50) | CNR1PTGS1KCNH2 | |
| SCHEMBL4126714 | 0.75 | DPP4 (0.43) | FPR2PIK3CDCNR1CNR2TRPA1 | |
| SCHEMBL1582483 | 0.74 | MEN1 (0.45) | FPR2PIK3CDCNR1CNR2TRPA1 | |
| SCHEMBL21844018 | 0.73 | FPR2 (0.34) | FPR2PIK3CDCNR1CNR2TRPA1 | |
| SCHEMBL4116094 | 0.73 | PTGS1 (0.30) | PTGS1KCNH2 | |
| SCHEMBL4125963 | 0.73 | PTGS1 (0.37) | PTGS1KCNH2 | |
| SCHEMBL19882810 | 0.72 | PIK3CD (0.39) | FPR2PIK3CDCNR1CNR2TRPA1 | |
| SCHEMBL29645831 | 0.72 | PIK3CD (0.39) | FPR2PIK3CDCNR1CNR2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | FPR2 229/4885PIK3CD 1651/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.